VectorY

The Amsterdam-based biotech, founded in 2020, is developing vectorized antibody therapies for neurodegenerative diseases. Its platform combines selective therapeutic antibodies with AAV-based delivery to the central nervous system, with programs in ALS, Huntington’s, and Parkinson’s disease.